View Older Stories View More Recent Stories

Jan 14, 2026 06:05AM BTIG Reiterates Buy Rating on Nurix (NRIX)
Jan 12, 2026 07:04AM NASDAQ: NRIX Nurix outlines 2026 goals for BTK degrader bexobrutideg
Jan 8, 2026 03:11AM Morgan Stanley Upgrades Nurix (NRIX) to Overweight
Jan 8, 2026 03:11AM Morgan Stanley Upgrades Nurix (NRIX) to Overweight
Dec 10, 2025 08:25AM Nurix (NRIX) PT Raised to $31 at H.C. Wainwright
Dec 10, 2025 04:13AM Nurix (NRIX) PT Raised to $30 at Mizuho
Dec 9, 2025 04:16AM Nurix (NRIX) PT Raised to $30 at BTIG
Dec 8, 2025 07:36AM Nurix's (NRIX) Bexdeg Potentially Best-in-Class - Stifel
Nov 7, 2025 09:02AM Nurix presents clinical data showing NX-1607 activates immune system
Oct 28, 2025 06:42AM Nurix (NRIX) PT Lowered to $28 at H.C. Wainwright
Oct 22, 2025 02:11PM Nurix (NRIX) PT Raised to $29 at RBC Capital
Oct 22, 2025 07:28AM Nurix begins pivotal study of bexobrutideg for blood cancer
Oct 20, 2025 04:06PM Mizuho Starts Nurix (NRIX) at Outperform, PT $24
Oct 20, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)
Oct 14, 2025 06:39AM Nurix (NRIX) PT Lowered to $33 at H.C. Wainwright
Oct 10, 2025 12:14PM Nurix (NRIX) PT Lowered to $33 at Stifel
Oct 10, 2025 08:19AM Nurix (NRIX) PT Lowered to $32 at Piper Sandler
Oct 10, 2025 05:22AM Nurix (NRIX) PT Lowered to $12 at Leerink Partners
Oct 9, 2025 04:02PM Nurix Therapeutics, Inc. (NRIX) Misses Q3 EPS by 20c
Sep 18, 2025 07:04AM Stifel Reiterates Buy Rating on Nurix (NRIX)
Sep 17, 2025 07:01AM Nurix Therapeutics presents preclinical data for GS-6791 IRAK4 degrader
Jul 14, 2025 10:11AM Nurix (NRIX) PT Lowered to $16 at Morgan Stanley
Jul 10, 2025 07:25AM Stifel Reiterates Buy Rating on Nurix (NRIX)
Jul 10, 2025 06:41AM Nurix (NRIX) PT Lowered to $26 at UBS
Jul 10, 2025 06:25AM Goldman Sachs Starts Nurix (NRIX) at Buy
Jul 10, 2025 06:12AM Stifel Reiterates Buy Rating on Nurix (NRIX)
Jul 1, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)
Jun 13, 2025 09:07AM UBS Reiterates Buy Rating on Nurix (NRIX)
Jun 13, 2025 09:02AM Nurix (NRIX) PT Raised to $28 at RBC Capital
Jun 3, 2025 06:26AM Stifel Reiterates Buy Rating on Nurix (NRIX)
Jun 2, 2025 11:14AM Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
Jun 2, 2025 07:01AM Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
Apr 25, 2025 01:01PM Nurix Therapeutics (NRIX) Presents Positive Preclinical Data
Apr 17, 2025 07:01AM Nurix Therapeutics (NRIX) Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Apr 10, 2025 10:23AM Nurix (NRIX) PT Lowered to $30 at UBS
Apr 9, 2025 08:00AM Nurix (NRIX) PT Lowered to $35 at Stifel
Apr 9, 2025 07:05AM Nurix (NRIX) PT Lowered to $30 at Stephens
Apr 9, 2025 05:28AM Stifel Reiterates Buy Rating on Nurix (NRIX)
Apr 9, 2025 05:15AM BTIG Reiterates Neutral Rating on Nurix (NRIX)
Apr 3, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)
Apr 2, 2025 07:03AM Nurix Therapeutics (NRIX) Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
Mar 17, 2025 07:01AM Nurix Therapeutics (NRIX) Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Mar 14, 2025 04:03PM Nurix Therapeutics (NRIX) announces inducement grants
Mar 13, 2025 04:00PM Nurix Therapeutics (NRIX) Appoints Roy D. Baynes to its Board
Jan 29, 2025 10:10AM Nurix (NRIX) PT Raised to $36 at Stifel
Jan 29, 2025 07:59AM Nurix (NRIX) PT Lowered to $28 at Needham
Jan 29, 2025 06:39AM Nurix (NRIX) PT Raised to $36 at H.C. Wainwright
Jan 28, 2025 04:23PM Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c
Jan 22, 2025 07:00AM Nurix Therapeutics (NRIX) Appoints John Northcott as Chief Commercial Officer
Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks
View More Recent Stories View Older Stories